NCT00709904 - Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery | Biotech Hunter

Enrollment

469

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Venous Thromboembolism

Interventions

DRUG

Open-label Semuloparin sodium

"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery"

DRUG

Placebo (for Semuloparin sodium)

"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection once daily"

DRUG

Semuloparin sodium

"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily"

Trial Locations (16)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Minsk

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Santiago

Sanofi-Aventis Administrative Office, Shangaï

Sanofi-Aventis Administrative Office, Bogotá

Sanofi-Aventis Administrative Office, Cairo

Sanofi-Aventis Administrative Office, Mumbai

Sanofi-Aventis Administrative Office, Vilnius

Sanofi-Aventis Administrative Office, México

Sanofi-Aventis Administrative Office, Lima

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Midrand

Sanofi-Aventis Administrative Office, Seoul

Sanofi-Aventis Administrative Office, Istanbul

Sanofi-Aventis Administrative Office, Kiev